Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report

Koichi Sugihara; Risa Wakiya; Hiromi Shimada; Mikiya Kato; Tomohiro Kameda; Shusaku Nakashima; Mai Mahmoud Fahmy Mansour; Yusuke Ushio; Norimitsu Kadowaki; Hiroaki Dobashi

doi:10.1186/s13223-021-00594-7

Interstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report

Allergy Asthma Clin Immunol. 2021 Sep 8;17(1):90. doi: 10.1186/s13223-021-00594-7.

Affiliations

¹ Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. [email protected].
² Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

Abstract

Background: Tocilizumab has been shown to be effective for treatment of juvenile idiopathic arthritis (JIA). To our knowledge, this is the first reported case of interstitial lung disease occurring shortly after tocilizumab infusion in a patient with JIA.

Case presentation: A 14-year-old female patient with polyarticular JIA developed interstitial lung disease after intravenous and subcutaneous administration of tocilizumab. Her condition improved with glucocorticoid therapy.

Conclusion: Our results suggest that increased interleukin-6 levels in the blood following tocilizumab treatment may be linked to development of interstitial lung disease.

Keywords: Drug-induced interstitial lung disease; Interleukin-6; Juvenile idiopathic arthritis; Tocilizumab.